scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

CS-IRG New Investigator Grant (CS-IRG-NIG) (Singapore)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
ERC webinar 2024

The CS-IRG New Investigator Grant (CS-IRG-NIG) from the Ministry Of Health and the National Medical Research Council (NMRC) of Singapore supports new investigator clinician-scientists in Singapore. The grant is open to applications in all research areas, with the following priority areas:

  • Cancers and neoplasms
  • Cardiovascular
  • Eye
  • Infection
  • Mental health
  • Metabolic and endocrine
  • Neurological

Applicants who are applying under the new investigator category (CS-IRG-NIG) have to work with a mentor for guidance in their research. Each CS-IRG application must be led by a Clinical Principal Investigator (PI) who meet the following critieria:

  • PI must be clinically qualified (i.e. with MD/MBBS/BDS) and preferably with post-graduate clinical training and experience;
  • Allied Health Professionals, including nurses and pharmacists;
  • A*STAR CS scholar from the National Science Scholarship (NSS) (MBBS-PhD) or NSS (MD-PhD) schemes;
  • For proposals involving patients, the clinical PI or co-I should be SMC registered;

The maximum grant amount is 260,000 SGD (inclusive of up to 30% indirect costs) for 2 -3 years. The grant has two calls per year, in January and in July.

The next applications close on January 31, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
scientifyRESEARCH
monthly funding newsletter

unsubscribe at any time